Article
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Cancer chemotherapy and pharmacology - 1 Apr 2017
Kashiwabara Kosuke, Semba Hiroshi, Fujii Shinji, Tsumura Shinsuke
Abstract excerpt
PURPOSE: Several non-small cell lung cancer (NSCLC) cases of successful rechallenge with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) after recovery from gefitinib or erlotinib-induced interstitial lung disease (ILD) have been reported, but it is not clear whether the rechallenge affects the outcome. METHODS: We retrospectively evaluated the difference in the outcome between advanced...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.